Comments
The board of Sun Pharmaceutical Industries on Tuesday approved the buy-back of its equity shares from the open market at a maximum price of ₹425 a share for an aggregate maximum amount of up to ₹1,700 crore. The buyback size represents 9.83 per cent and 4.44 per cent of the total paid-up equity share capital and free reserves of the latest audited standalone financial statements and audited consolidated financial statements, respectively, for the financial year ended March 31, 2019. The company will buy back from the equity shareholders/beneficial owners of equity shares of the company, except promoters, members of promoter group and persons acting in concert. Our Bureau
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.